Nebulized salbutamol (Asmasal) in Thai children with asthma: comparison of three doses.
Asian Pac J Allergy Immunol
;
1994 Jun; 12(1): 7-13
Article
in English
| IMSEAR
| ID: sea-36661
ABSTRACT
Eleven moderate-to-severe asthmatic children 5-11 years of age who were in stable condition were given (randomly, double-blind) nebulized salbutamol sulfate (Asmasal) inhalation therapy at doses of 0.1, 0.2 and 0.3 mg/kg body weight on separated days. All three doses of nebulized solution resulted in clinical improvement and improvement of lung function (FEV1, FVC, PEFR and FEF25-75%). A dose of 0.3 mg/kg produced greatest improvement and longest duration of improvement in FEV1 and PEFR, but the change was statistically significant only in PEFR at 60 minutes (p < 0.05). Five children experienced mild tremors. There were no significant changes in heart rate or blood pressure at any dose. It is concluded that a nebulized solution of salbutamol sulfate at a dose of 0.1-0.3 mg/kg is useful for treatment of asthma in Thai children, with very mild side effects.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Asthma
/
Thailand
/
Administration, Inhalation
/
Female
/
Humans
/
Male
/
Child
/
Double-Blind Method
/
Cross-Over Studies
/
Pulmonary Ventilation
Type of study:
Controlled clinical trial
Country/Region as subject:
Asia
Language:
English
Journal:
Asian Pac J Allergy Immunol
Year:
1994
Type:
Article
Similar
MEDLINE
...
LILACS
LIS